DiaSorin tries to recover ground in Piazza Affari after the publication of the quarterly report with increasing turnover and profitability. The Italian diagnostics group closed the first quarter of 2021 with a turnover that rose by 52.7% to 266.7 million euros (+ 59.5% at constant exchange rates). “The growth – explains the company – was driven by sales of tests for SARS-CoV-2, equal to 102 million and by the important recovery of the ex-Covid business, which recorded a turnover in line with the first quarter of 2020 “. In the quarter, adjusted Ebitda jumped 101% to 129.6 million, and Ebit jumped to 103.3 million (+ 109.1% yoy). Net profit, on the other hand, grew by 107.2% to 78.2 million.
As regards the 2021 guidance (at constant exchange rates), the company expects revenues to grow between 15% and 25%, of which ex-Covid revenues up by about 15% and an adjusted EBITDA margin. between 44% and 47%.